Jonathan David Schwartz - 18 Aug 2025 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
Chief Medical & Gene Therapy Officer
Signature
/s/ Martin Wilson, as attorney-in-fact for Jonathan David Schwartz
Issuer symbol
RCKT
Transactions as of
18 Aug 2025
Net transactions value
-$7,561
Form type
4
Filing time
20 Aug 2025, 17:00:22 UTC
Previous filing
18 Aug 2025
Next filing
09 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Schwartz Jonathan David Chief Medical & Gene Therapy Officer C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY /s/ Martin Wilson, as attorney-in-fact for Jonathan David Schwartz 20 Aug 2025 0001726398

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCKT Common Stock Sale $5,149 -1,680 -0.75% $3.06 222,414 18 Aug 2025 Direct F1, F2
transaction RCKT Common Stock Sale $2,412 -805 -0.36% $3.00 221,609 19 Aug 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
F2 The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Remarks:

Chief Medical & Gene Therapy Officer